

# The EU regulation on health technology assessment: what's in it and why it matters?" HTA information on health technology assessment: What's in it and why it matters?"

HTA information day, Athens 18 September 2023



## What is health technology assessment?

Health technology assessment (HTA) is the systematic evaluation of the properties, effects, or impact of a health technology in comparison to another technology.



HTA considers evidence about medical, economic, social and ethical issues related to the use of a health technology.



### **HTA domains**

**HTA** domains **Health problem and currently used technologies Description of technology under assessment Clinical domains Relative clinical effectiveness Relative safety Economic evaluation Ethical aspects Organisational aspects Non-clinical domains Social aspects Legal aspects** 



## Regulatory process vs. HTA





- Single EU legislation
- Well defined and agreed assessment criteria



- All Member States have different HTA systems
- National legislations and procedures
- Different methodologies and assessment criteria



**AGENAS** 

## Regulatory process vs. HTA



## EU HTA regulation

### NATIONAL

- Single licensing system
- Single EU legislation
- Well defined and agreed assessment criteria
- Joint framework for HTA
- and approach for clinical assessments and scientific consultations
- Use of joint clinical assessment in national decision-making
- Non-clinical assessments
- Decision making on pricing and reimbursements



## Strengthening EU HTA cooperation

/05/2015



Brussels, 10 November 2016

HTA NETWORK REFLECTION PAPER ON
"SYNERGIES BETWEEN REGULATORY AND HTA
ISSUES ON PHARMACEUTICALS"

ADOPTED BY THE HTA NETWORK, 10 NOVEMBER 2016

HTA NETWORK REFLECTION PAPER ON "REUSE OF JOINT WORK IN NATIONAL HTA ACTIVITIES"

ADOPTED BY THE HTA NETWORK, APRIL 2015



JA1 (2010 – 2012) JA2 (2012 – 2015) JA3 (2016 – 2021)



## HTA Regulation



## Regulation (EU) 2021/2282 on HTA

- ❖Adoption 15 December 2021
- Entry into force 11 January 2022
- Entry into application 12 January 2025
- ❖ Main objectives: establishing a support framework and procedures for cooperation of Member States on health technologies at Union level; a mechanism for the submission of evidence for joint clinical assessments only once at Union level; common rules and methodologies for joint clinical assessments.



## HTA Regulation – Key principles

- Joint work on common scientific, clinical aspects of HTA
- Driven by Member State HTA bodies
- Ensure high quality, timeliness and transparency
- Ensure involvement of stakeholders
- Ensure use of joint work in national HTA processes
- Member States remain responsible for:
  - Drawing conclusions on added value for their health system
  - Taking decisions on pricing & reimbursement
- Addresses experts and stakeholders' engagement in joint work
- Progressive implementation



### **Joint HTA activities**

### Joint Clinical Assessments (JCA) on:

 medicines <u>first 3 years</u>: cancer medicines and advanced therapy medicinal products

from January 2028: + orphan medicinal products


from 2030: full scope

- a selection of high-risk medical devices and in-vitro medical devices Joint Scientific Consultations (JSC)
  - in parallel with the European Medicines Agency

**Emerging Health Technologies Methodology for joint HTA work Voluntary cooperation** 




### Governance



European


Commission

## Type of organisations in the HTA Stakeholder Network





## Halfway through the preparatory phase





Service contract EUnetHTA21

Awareness raising, incl. HTA information events (regional)



## Implementing acts to be adopted by 2025

Procedural rules for JCA medicinal products	Q4 2023
Procedural rules for the prevention of conflict of interest	Q1 2024
Cooperation by exchange of information with the EMA	Q1 2024
Procedural rules for JSC medicinal products	Q2 2024
Procedural rules for JCA medical devices and IVD medical devices	Q3 2024
Procedural rules for JSC medical devices and IVD medical devices	Q4 2024



## Preparation, consultation and adoption of implementing acts

### **Early reflection**

The Commission carries out appropriate consultations during its preparatory work.

'Comitology' (examination) procedure

HTA Committee
provides opinion on
the draft text

### **Targeted consultation**

Consultations with relevant stakeholders.


### **Public consultation**

Consultations with all stakeholders on <u>Have your Say</u> (4-week feedback period)



Collaboration with EMA under the HTA

regulation






## Collaboration with EMA under the HTA regulation



Life-cycle evidence planning




Cross-decision making collaboration



Communication and training



Research projects and policy initiatives



Processes under the Regulation



## Rolling plan regularly updated

#### IMPLEMENTATION ROLLING PLAN

#### 2023-2024

#### REGULATION (EU) 2021/2282 ON HEALTH TECHNOLOGY ASSESSMENT

This rolling plan contains a list of key activities that the Commission has carried out or intends to carry out in preparation for the implementation of Regulation 2021/2282 on Health Technology Assessment (the "HTAR"). The plan is subject to regular review to provide national authorities and stakeholders with the most updated information.

The HTAR entered into force on January 11, 2022. It will be applicable as of January 12, 2025.

#### Latest update: June 2023

SUBJECT	LEGAL BASIS	DESCRIPTION	EXPECTED TIMELINE	STATUS	
Member State Coordination Group on Health Technology Assessment (HTACG)					
HTAR Article 3					
Fourth meeting of the	HTAR Article 3		13 June 2023	In	
HTACG				preparation	
Third meeting of the			6 July 2023	In	
subgroup on methodological				preparation	
and procedural guidance					
Third meeting of the			7 July 2023	In	
subgroup on Joint Clinical				preparation	
Assessments					
Third meeting of the			6 October 2023	In	
subgroup on Joint Scientific				preparation	
a trait					

https://health.ec.europa.eu/health-technology-assessment\_en



## Awareness raising – HTA information events







## Conclusions: Co-creation of a new system

Inclusiveness and transparency as key principles of the joint work

Commitment of all Member States and all stakeholders is essential to secure smooth implementation

16 months left until application



## Thank you for your attention

### Any question?

Bela.DAJKA@ec.europa.eu

SANTE-HTA@ec.europa.eu

### © European Union 2022

Unless otherwise noted the reuse of this presentation is authorised under the <u>CC BY 4.0</u> license. For any use or reproduction of elements that are not owned by the EU, permission may need to be sought directly from the respective right holders.

